The price of entrectinib varies depending on the region, health insurance policy, dosage, and purchase channel. The specific monthly treatment cost needs to be determined based on the patient's actual situation and local policies. This is a prescription drug and must be used strictly according to the doctor's instructions. Dosage adjustments or discontinuation are not permitted without medical supervision.
Price Influencing Factors
Health Insurance Reimbursement: Entrectinib is included in the health insurance catalogs of some regions. Patients meeting the indications (such as NTRK gene fusion-positive solid tumors and ROS1-positive non-small cell lung cancer) can be reimbursed for a portion of the cost. The co-payment ratio varies depending on regional policies.
Dosage and Treatment Duration: The recommended dose is 600 mg daily, based on the patient's weight and condition. Differences in unit price between different strengths (e.g., 100 mg/tablet, 200 mg/tablet) will affect the total monthly treatment cost.
Purchase Channels: Hospitals, designated pharmacies, or specific charitable drug donation programs may offer price discounts. Some patients can alleviate their financial burden through assistance programs.
International Price Reference
US Market: Monthly costs are significantly higher than in the Chinese market.
In regions like India: Generic drugs are cheaper, but attention should be paid to drug compliance and safety issues.
Medical Treatment and Medication Guidance
Entrectinib requires a prescription from an oncologist after evaluating genetic testing results. Patients need regular check-ups to monitor efficacy and side effects (such as dizziness, fatigue, abnormal liver function, etc.).
Patients with financial difficulties can apply for patient assistance programs from hospital social workers or pharmaceutical companies. Some programs offer drug cost reductions or installment payment options.
Precautions
Avoid concurrent use with potent CYP3A inhibitors or inducers during treatment to avoid affecting blood drug concentrations.
Contraindicated in pregnant women, breastfeeding women, and patients with severe hepatic or renal impairment.
Patients are advised to obtain medication from reputable medical institutions and consult their attending physician or pharmacist for the latest pricing and reimbursement policies.
